Classifying new anti-tuberculosis drugs: Rationale and future perspectives [PDF]
, 2016 The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter ...
Caminero Luna, JA +10 more
core
Infection and Drug Resistance, 2023 Tianhui Gao,1,* Cong Yao,1,* Yuanyuan Shang,1 Renchun Su,1 Xuxia Zhang,1 Weicong Ren,1 Shanshan Li,1 Wei Shu,2 Yu Pang,1 Qi Li2 1Department of Bacteriology and Immunology, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Gao T +9 more
doaj
Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches [PDF]
, 2017 Peptides of varied origins such as human immune cells and non-immune cells, bacteria, fungi, and venoms have been widely investigated as anti-tubercular agents for the replacement of existing anti-tubercular drugs in future.
Aarti, Chirom +7 more
core
2016 Pipeline Report HIV and TB [PDF]
, 2016 HIV and TB: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in ...
Erica Lessem +7 more
core
Tuberculosis 110 years after the Nobel Prize awarded to Koch [PDF]
, 2015 Robert Koch recibió el Premio Nobel por sus investigaciones y descubrimientos sobre la tuberculosis (TB) en 1905. Descubrió su agente causal, describió los cuatro postulados que guiaron desde entonces las investigaciones en enfermedades transmisibles y ...
Kantor, Isabel N. +1 more
core
Optimising linezolid use for drug-resistant tuberculosis: pharmacokinetics, toxicity, and resistance [PDF]
, 2022 Background: Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. There is a need for more effective, safe, and well-tolerated drugs. Linezolid is
Wasserman, Sean Adam
core +1 more source
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis [PDF]
Accelerated tuberculosis drug discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments.
Chaba, Linda +7 more
core +1 more source
The Tuberculosis Treatment Pipeline: Activity, but No Answers [PDF]
, 2016 In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial that includes the new drug pretomanid),
Erica Lessem
core
Candidate anti-tuberculosis medicines and regimens under clinical evaluation [PDF]
Background: Tuberculosis (TB) is the leading cause of mortality by an infectious disease worldwide. Despite national and international efforts, the world is not on track to end TB by 2030.
Barros-Aguirre, David +7 more
core +1 more source
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies [PDF]
, 2018 Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant
du Plessis, N +13 more
core +1 more source